Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
The MET pathway plays a key role in various cancers, and its inhibition represents a potential treatment target. However, appropriate biomarkers are needed to facilitate the selection of patients who would benefit from MET inhibiting therapy. We herein conducted a robust confirmatory evaluation of t...
Main Authors: | Cho, Yoon Ah, Kim, Eun Kyung, Heo, Su Jin, Cho, Byoung Chul, Kim, Hye Ryun, Chung, Ji Myung, Yoon, Sun Och |
---|---|
Format: | Online |
Language: | English |
Published: |
Ivyspring International Publisher
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166528/ |
Similar Items
-
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
by: Kim, Hye Ryun, et al.
Published: (2016) -
Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
by: Huang, Kie Kyon, et al.
Published: (2016) -
Role of Met Axis in Head and Neck Cancer
by: Xu, Yiru, et al.
Published: (2013) -
Association of the GSTP1 and NQO1 Polymorphisms and Head and Neck Squamous Cell Carcinoma Risk
by: Cho, Chang Gun, et al.
Published: (2006) -
Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck
by: Boucek, Jan, et al.
Published: (2010)